Conti, Ilaria
(2019)
Human Parvovirus B19: from the development of a reverse genetics system to antiviral strategies, [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Scienze biotecnologiche e farmaceutiche, 31 Ciclo. DOI 10.6092/unibo/amsdottorato/8773.
Documenti full-text disponibili:
|
Documento PDF (English)
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (5MB)
|
Abstract
Human Parvovirus B19 (B19V) is a human pathogenic virus and responsible for various clinical manifestations, although neither an antiviral therapy nor a vaccine are available. Difficulties for B19V propagation and characterization are caused by its narrow tropism for the erythroid progenitor cells of human bone marrow and the very few cell lines that can support the viral replication.
In this research, a reverse genetic approach was first developed to allow the generation of mature and infectious viral particles from a designed viral consensus sequence. Synthetic clones that differ for their terminal regions (ITRs) were constructed, transfected in UT7/EpoS1 cells and the obtained viral particles were used to infect EPCs (erythroid progenitor cells) in serial passages. Mature and functional viral particles were obtained by clones containing the almost full length ITRs and by clones codifying shorter ITRs, extended till the internal symmetry sites but with different sequence isomerisms.
Cellular factors and machinery change along the eryhroid differentiation probably influencing and delimiting the cellular susceptibility and permissiveness to the virus. In face of the limited fraction of B19V productively infected cells, the expression of the globoside receptor, the coreceptor, the endocytosis and the EpoR pathway was commonly detected among both EPCs and UT7/EpoS1 cells during this research, suggesting the involvement of other cellular factors.
Characterization of both the virus and cells allows investigation of new strategies for the development of specific antiviral compounds. In this research, the retargeted drug Hydroxyurea and especially the broad range analogue Brincidofovir showed a B19V antiviral activity. Small-scale screening of newly synthesized molecules led to identification of few compounds with suboptimal activity. The computational predictions of G-quadruplex structures within the B19V ITRs was not corroborated by chemical and biological studies excluding any their relevant role in the viral lifecyle.
Abstract
Human Parvovirus B19 (B19V) is a human pathogenic virus and responsible for various clinical manifestations, although neither an antiviral therapy nor a vaccine are available. Difficulties for B19V propagation and characterization are caused by its narrow tropism for the erythroid progenitor cells of human bone marrow and the very few cell lines that can support the viral replication.
In this research, a reverse genetic approach was first developed to allow the generation of mature and infectious viral particles from a designed viral consensus sequence. Synthetic clones that differ for their terminal regions (ITRs) were constructed, transfected in UT7/EpoS1 cells and the obtained viral particles were used to infect EPCs (erythroid progenitor cells) in serial passages. Mature and functional viral particles were obtained by clones containing the almost full length ITRs and by clones codifying shorter ITRs, extended till the internal symmetry sites but with different sequence isomerisms.
Cellular factors and machinery change along the eryhroid differentiation probably influencing and delimiting the cellular susceptibility and permissiveness to the virus. In face of the limited fraction of B19V productively infected cells, the expression of the globoside receptor, the coreceptor, the endocytosis and the EpoR pathway was commonly detected among both EPCs and UT7/EpoS1 cells during this research, suggesting the involvement of other cellular factors.
Characterization of both the virus and cells allows investigation of new strategies for the development of specific antiviral compounds. In this research, the retargeted drug Hydroxyurea and especially the broad range analogue Brincidofovir showed a B19V antiviral activity. Small-scale screening of newly synthesized molecules led to identification of few compounds with suboptimal activity. The computational predictions of G-quadruplex structures within the B19V ITRs was not corroborated by chemical and biological studies excluding any their relevant role in the viral lifecyle.
Tipologia del documento
Tesi di dottorato
Autore
Conti, Ilaria
Supervisore
Dottorato di ricerca
Ciclo
31
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Parvovirus B19, consensus sequence, reverse genetics, synthetic clones, infectious clones, cellular markers, permissiveness, susceptibility, hydroxyurea, brincidofovir, small-scale screening, BRACO-19, Pyridostatin, G-quadruplexes, circular dychroism, antiviral activity, erythroid progenitor cells, UT7/EpoS1 cells
URN:NBN
DOI
10.6092/unibo/amsdottorato/8773
Data di discussione
28 Marzo 2019
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Conti, Ilaria
Supervisore
Dottorato di ricerca
Ciclo
31
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Parvovirus B19, consensus sequence, reverse genetics, synthetic clones, infectious clones, cellular markers, permissiveness, susceptibility, hydroxyurea, brincidofovir, small-scale screening, BRACO-19, Pyridostatin, G-quadruplexes, circular dychroism, antiviral activity, erythroid progenitor cells, UT7/EpoS1 cells
URN:NBN
DOI
10.6092/unibo/amsdottorato/8773
Data di discussione
28 Marzo 2019
URI
Statistica sui download
Gestione del documento: